Peripheral benzodiazepine receptors and diazepam binding inhibitor in lymphocytes of demented patients

C. Ferrarese, A. Bianchetti, A. Scuratti, G. Bianchi, R. Cavarretta, R. Riva, M. Frigo, N. Pecora, G. Frisoni, A. Frattola, M. Trabucchi

Research output: Contribution to journalArticlepeer-review


Since modifications of peripheral benzodiazepine receptors (PBR) and their ligand diazepam binding inhibitor (DBI) have been described in brain and cerebrospinal fluid of Alzheimer disease (AD) patients, we investigated these parameters in circulating lymphocytes of demented patients, as possible peripheral markers of neurochemical alterations. 15 AD, 11 multi-infarct dementia (MID), 20 Parkinson's Disease (PD) patients and 10 age-matched normal controls were selected for lymphocyte preparation. PBR density and affinity were measured by the specific binding of [H3]PK-11195, selective ligand of these receptors, and DBI levels were measured by a specific radioimmunoassay. PBR density was highly variable in AD patients, reduced in MID and similar to controls in PD patients. The same modifications were observed for DBI levels. As observed for other neurochemical markers, these findings reveal a biochemical heterogeneity in AD, which may explain different therapeutic responses to various drugs; the significant decrease of these values observed in ischaemic vascular dementia might be related to systemic metabolic alterations.

Original languageEnglish
Pages (from-to)129-131
Number of pages3
JournalAlzheimer's Research
Issue number4
Publication statusPublished - 1996


  • Alzheimer's disease
  • Benzodiazepine receptors
  • DBI
  • Dementia
  • Lymphocytes

ASJC Scopus subject areas

  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology


Dive into the research topics of 'Peripheral benzodiazepine receptors and diazepam binding inhibitor in lymphocytes of demented patients'. Together they form a unique fingerprint.

Cite this